In a 6-3 ruling handed down on Monday, March 2, the U.S. Supreme Court's GOP-appointed supermajority ruled to uphold a congressional map favoring Rep. Nicole MalliotakisIn a 6-3 ruling handed down on Monday, March 2, the U.S. Supreme Court's GOP-appointed supermajority ruled to uphold a congressional map favoring Rep. Nicole Malliotakis

How Justice Alito set a 'disturbing precedent' for core American right

2026/03/04 03:19
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

In a 6-3 ruling handed down on Monday, March 2, the U.S. Supreme Court's GOP-appointed supermajority ruled to uphold a congressional map favoring Rep. Nicole Malliotakis (R-New York) — who serves in the U.S. House of Representatives via parts of Staten Island and Brooklyn. The ruling in Malliotakis v. Williams overturned a previous decision by a judge who decided that the map discriminated against Black and Latino voters in New York City.

The ruling came down along partisan lines, with Justices Elena Kagan and Ketanji Brown Jackson joining fellow Democratic appointee, Sonia Sotomayor, in her dissenting opinion. All six of the High Court's GOP appointees sided with Malliotakis.

Mother Jones' Ari Berman offers a biting critique of the ruling in an article published on March 3, arguing that Justice Samuel Alito's opinion is an ominous sign for voting rights.

Sotomayor, Berman notes, "blasted the Court's conservative majority for using one set of rules to uphold redistricting maps that benefit white voters and Republicans in states like Texas while using a completely different set of rules to strike down maps that benefit racial minorities and Democrats in places like New York."

"The majority did not explain its reasoning," according to Berman, "but most concerning was the concurring opinion by Justice Samuel Alito, in which he wrote that districts drawn 'for the express purpose of ensuring that minority voter are able to elect the candidate of their choice' represented 'unadorned racial discrimination, an inherently odious activity that violates the Fourteenth Amendment's Equal Protection Clause except in the most extraordinary case.' Alito is essentially saying that districts drawn under the Voting Rights Act or other federal and state laws to remedy centuries of racial discrimination are as racist as the racism, including the legacy of slavery and Jim Crow, they were meant to rectify."

Berman continues, "Court watchers speculate that Alito, because he has not authored an opinion from the Court's term last October, is writing the majority opinion in a hugely important case the Court has yet to rule on concerning the constitutionality of the last remaining section of the Voting Rights Act. If that's the case, the VRA — and by extension, the fate of American democracy — will be in very, very bad shape."

The Voting Rights Act of 1965, signed into law by President Lyndon B. Johnson, forbids racial discrimination in voting and was a landmark part of the Great Society — LBJ's expansion of President Franklin Delano Roosevelt's New Deal.

Alito, Berman warns, "seems certain to kill the VRA outright or narrow it to the point of irrelevancy."

"If the Court were to rule against the VRA this spring," the Mother Jones journalist writes, "that could shift roughly a dozen seats in the GOP's favor this year, turbocharging Trump's efforts to manipulate the midterms. Alito is now telegraphing just how far he's prepared to go."

  • george conway
  • noam chomsky
  • civil war
  • Kayleigh mcenany
  • Melania trump
  • drudge report
  • paul krugman
  • Lindsey graham
  • Lincoln project
  • al franken bill maher
  • People of praise
  • Ivanka trump
  • eric trump
Market Opportunity
AssangeDAO Logo
AssangeDAO Price(JUSTICE)
$0.0000166
$0.0000166$0.0000166
-0.06%
USD
AssangeDAO (JUSTICE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09